Test your knowledge of Tudriqev’s accelerated approval, clinical activity, administration, and ongoing confirmatory research.
Joan Levy, PhD
Advertisement
Joan Levy, PhD, serves as the Chief Science Officer for the Melanoma Research Alliance
Articles by Joan Levy, PhD
Joan Levy, PhD, chief science officer at the Melanoma Research Alliance, discussed the significance of Tudriqev's accelerated approval for patients with anti-PD-1-refractory melanoma.
Advertisement
Latest Updated Articles
Q&A: What Tudriqev's Approval Means for PD-1-Refractory MelanomaAugust 19th 2026
Advertisement
Advertisement
Trending on Dermatology Times
1
Delgocitinib Shows Real-World Effectiveness and Improved Quality of Life in Chronic Hand Eczema
2
EADV 2026 Day 3: Long-Term Psoriasis Data and Emerging Therapeutic Targets Take Focus
3
Obefazimod Data Across Phase 3 and Long-Term Studies to Be Presented at UEG Week 2026
4
EADV 2026 Day 2: Long-Term AD Data, GLP-1 Nail Findings, and Emerging Treatments Take Center Stage
5